A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge

Journal of Medicinal Chemistry

Volumn 45, Issue 20, 2002, Pages 4391-4394

  Grieco, Paolo ^a   Carotenuto, Alfonso ^b   Campiglia, Pietro ^a   Zampelli, Enrico ^b   Patacchini, Riccardo ^c   Maggi, Carlo A ^c   Novellino, Ettore ^a   Rovero, Paolo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR AGONIST;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DISULFIDE BOND; DRUG ACTIVITY; DRUG CONFORMATION; DRUG MANUFACTURE; DRUG POTENCY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CYSTEINE; DISULFIDES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; PENICILLAMINE; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037179641     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025549i     Document Type: Article

References (29)

1. Pearson, D.; Shively, J. E.; Clark, B. R.; Geschwind, I. I.; Barkley, M.; Nishioka, R. S.; Bern, H. A. Urotensin II: a somatostain-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5021-5024.
2. Coulouarn, Y.; Lihrmann, I.; Jegou, S.; Anouar, Y.; Tostivint, H.; Beauvillain, J. C.; Conlon, J. M.; Bern, H. A.; Vaudry, H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15803-15808.
3. Itoh, H.; Itoh, Y.; Rivier, J.; Lederis, K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol. 1987, 252, R361-R366.
4. (a) Ames, R. S.; Sarau, H. M.; Chambers, J. K.; Willette, R. N.; Aiyar, R. V.; Romanic, A. M.; Louden, C. S.; Foley, J. J.; Sauermelch, C. F.; Coatney, R. W.; Ao, Z.; Disa, J.; Holmes, S. D.; Stadel, J. M.; Martin, J. D.; Liu, W.-S.; Glover, G. I.; Wilson, S.; McNutty, D. E.; Ellis, C. E.; Eishourbagy, N. A.; Shabon, U.; Trill, J. J.; Hay, D. V. P.; Ohlstein, E. H.; Bergsma, D. J.; Douglas, S. A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401, 282-286.
5. (b) Nothacker, H. P.; Wang, Z.; McNeill, A. M.; Saito, Y.; Merten, S.; O'Dowd, B.; Duckles, S. P.; Civelli, O. Identification of the natural ligand of an orphan G-protein coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol. 1999, 1, 383-385.
6. (c) Mori, M.; Sugo, T.; Abe, M.; Shimomura, Y.; Kurihara, M.; Kitada, C.; Kikuchi, K.; Shintai, Y.; Kurokawa, T.; Onda, H.; Nishimura, O.; Fujino, M. Urotensin II is the endogenous ligand of a G-protein coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 1999, 265, 123-129.
7. (d) Liu, Q.; Pong, S.-S.; Zeng, Z.; Zhang, Q.; Howard, A. D.; Williams, D. R.; Davidoff, M.; Wang, R.; Austin, C. P.; McDonald, T. P.; Bai, C.; George, S. R.; Evans, J. F.; Caskey, C. T. Identification of urotensin II as the endogenous ligand for the orphan G-protein coupled receptor GPR14. Biochem. Biophys. Res. Commun. 1999, 266, 174-178.
8. (a) MacLean, M. R.; Alexander, D.; Stirrat, A.; Gallagher, M.; Douglas, S. A.; Ohlstein, E. H.; Morecroft, I.; Polland, K. Contractile response to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol. 2000, 130, 201-204.
9. (b) Maguire, J. J.; Kuc, R. E.; Davenport, A. P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 2000, 131, 441-446.
10. (c) Douglas, S. A.; Ohlstein, E. H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardivascular diseases. Trends Cardiovasc. Med. 2000, 10, 229-237.
11. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
12. Misika, A.; Hruby, V. J. Optimization of disulfide bond formation. Pol. J. Chem. 1994, 68, 893-899.
13. Camarda, V.; Rizzi, A.; Calò, G.; Gendron, G.; Perron, S. I.; Kostenis, E.; Zamboni, P.; Mascoli, F.; Regoli, D. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 365, 141-149.
14. Piantini, U.; Sorensen, O. W.; Ernst, R. R. Multiple quantum filters for elucidating NMR coupling network. J. Am. Chem. Soc. 1982, 104, 6800-6801.
15. Bax, A.; Davis, D. G. Practical aspect of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 1985, 63, 207-213.
16. Jeener, J.; Meyer, B. H.; Bachman, P.; Ernst, R. R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 1979, 71, 4546-4553.
17. Guntert, P.; Mumenthaler, C.; Wuüthrich, K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. J. Mol. Biol. 1997, 273, 283-298.
18. Grieco, P.; Patacchini, R.; Carotenuto, A.; Maggi, C. A.; Novellino, E.; Rovero, P. Design, synthesis and conformational analysis of human urotensin II analogues with lactam bridge. In Peptides: The Wave of the Future; Lebl, M., Houghten, R. A., Eds.; American Peptide Society: San Diego, CA, 2001; pp 630-631.
19. Meraldi, J. P.; Hruby, V. J.; Brewster, A. I. R. Relative conformational rigidity in oxytocin and [1-penicillamine]-oxytocine: a proposal for relationship of conformational flexibility to peptide hormone agonism and antagonism. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 1373-1377.
20. Hruby, V. J. Conformational and topographical consideration in the design of biologically active peptides. Biopolymers 1993, 33, 1073-1082.
21. (a) Hruby, V. J.; Li, G.; Haskell-Luevano, C.; Shenderovich, M. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 1997, 43, 219-266.
22. (b) Hruby, V. J.; Yamamura, H. I.; Porreca, F. Molecular organization of receptors. Ann. N.Y. Acad. Sci. 1995, 757, 7-21.
23. (a) Schulz, H.; Du Vigneaud, V. Synthesis of 1-L-penicillamine-oxytocin, 1-D-penicillamine-oxytocin, and 1-deaminopenicillamine-oxytocin, potent inhibitors of the oxytocic response to oxytocin. J. Med. Chem. 1966, 9, 647-650.
24. (b) Schulz, H.; Du Vigneaud, V. Synthesis and some pharmacological properties of 6-L-penicillamine-oxytocin. J. Med. Chem. 1967, 10, 1037-1039.
25. (c) Chan, W. Y.; Hruby, V. J.; Du Vigneaud, V. Effects of magnesium ions and oxytocin inhibitors on the uterotonic activity of oxytocin and prostaglandins E2 and F2α. J. Pharmacol. Exp. Ther. 1974, 190, 77-87.
26. (a) Pelton, J. T.; Gulya, K.; Hruby, V. J.; Duckles, S.; Yamamura, H. I. Somatostatin analogs with affinity for opiate receptors in rat brain binding assay. Peptides 1985, 6, 159-163.
27. (b) Kazmierski, W.; Hruby, V. J. A new approch to receptor ligand design: synthesis and conformation of a new class of potent and highly selective μ opioid antagonists utilizing tetrahydroisoquinoline carboxylic acid. Tetrahedron 1988, 44, 697-710.
28. 5]enkephalin. J. Med. Chem. 1991, 34, 1823-1830.
29. Saha, S.; Waugh, D. J. J.; Zhao, P.; Abel, P. W.; Smith, D. D. Role of conformational constraints of position 7 of the versus antagonist properties. J. Pept. Res. 1998, 52, 112-120.